March 2026 Quarterly Activities Report and Appendix 4C
Filed with ASX · · 10 pages · English
Summary by 6ix AI
The report highlights the company's national expansion of its Empax clinic network and the launch of a Global Partnership Program aimed at supporting international drug sponsors. Emyria reported revenue growth driven by increased clinic utilization and insurer-funded patient demand, alongside significant clinical outcomes for PTSD treatments. The company is well-positioned for future growth with plans for further clinic activations and expansion into New South Wales, Australia's largest patient market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Emyria
- Emyria Launches Global Partnership Program
- EMD Commences NSW Workforce Recruitment To Support Expansion
- Key Milestones Achieved for First Victorian Empax Clinic
- Appendix 4D and Half Year End Financial Report
- Medibank Expands Funding to Emyria's Victorian Clinic
Later from Emyria
- Emyria Extends National Expansion into New South Wales
- March Quarter Investor Video Presentation
- Emyria Activates First Victorian Empax Clinic
- TGA Update to Accelerate Empax Therapist Recruitment
- Emyria Company Update Presentation
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria